HAO:NSD-Haoxi Health Technology Limited Class A Ordinary Shares (USD)

COMMON STOCK | Advertising Agencies |

Last Closing

USD 0.3301

Change

-0.03 (-8.33)%

Market Cap

N/A

Volume

1.08M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Advertising Agencies

Symbol Name Price(Change) Market Cap
ADVWW Advantage Solutions Inc

-0.01 (-18.47%)

USD 3.69B
CRTO Criteo Sa

-0.08 (-0.20%)

USD 2.27B
ZD Ziff Davis Inc

-1.24 (-2.55%)

USD 2.19B
MGNI Magnite Inc

-1.49 (-10.76%)

USD 1.94B
STGW Stagwell Inc

+0.09 (+1.28%)

USD 1.88B
IAS Integral Ad Science Holding LL..

-0.26 (-2.41%)

USD 1.78B
ADV Advantage Solutions Inc

-0.11 (-3.21%)

USD 1.10B
QNST QuinStreet Inc

-0.33 (-1.73%)

USD 1.07B
NCMI National CineMedia Inc

-0.25 (-3.55%)

USD 0.69B
NEXN Nexxen International Ltd

-0.20 (-2.49%)

USD 0.41B

ETFs Containing HAO

N/A

Market Performance

  Market Performance vs. Industry/Classification (Advertising Agencies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain -98.69% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.69% 3% F 1% F
Trailing 5 Years  
Capital Gain -98.61% 7% C- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.61% 7% C- 4% F
Average Annual (5 Year Horizon)  
Capital Gain -9.09% N/A N/A 26% F
Dividend Return -8.92% N/A N/A 26% F
Total Return 0.18% N/A N/A 6% D-
Risk Return Profile  
Volatility (Standard Deviation) 25.82% N/A N/A 68% D+
Risk Adjusted Return -34.53% N/A N/A 22% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:

There is nothing we particularly dislike